Global Veterinary Artificial Insemination Market - 2022-2029

Global Veterinary Artificial Insemination Market - 2022-2029

Market Overview

Veterinary Artificial Insemination Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Artificial insemination involves creating a pregnancy without engaging in sexual activity by injecting sperm or semen into the female uterus or cervix. By using fresh, uncooked, or frozen semen straw, it is possible to breed cattle. In vivo fertilization uses artificial insemination to make an animal pregnant. Because it works better during the animal's heat cycle, this technique is also employed in sperm donation and reproductive technology, allowing animals to reproduce on schedule. Enhancing the genetics and reproduction of animals using veterinary artificial insemination is a unique biotechnology approach.

Market Dynamics

Technological advancement in veterinary artificial insemination applications is expected to drive market growth.

The University of Florida created the Market Oriented Dairy (MOD) Ration Formulation Tool (RAFT) mobile application. Before being used by farmers in Rwanda to build a balanced ration for their dairy cattle, the software, which is available in iOS and Android versions, will be tailored for the country's needs. After artificial insemination or natural mating, a solution to help farmers determine the pregnant state of cattle is proposed in the second section. A non-pregnant cow can resume mating or artificial insemination as soon as feasible with the early diagnostic technique. With this technique, farmers can ensure that each of their cows produces a calf yearly, achieving breeding efficiency. Moreover, this effectiveness will guarantee that cows produce more milk throughout their lives and benefit farmers. Thus, from the above statements, the market is expected to boost in the forecast period.

Restraint

Risks related to animal breeding, including the spread of disease and infection, a lack of qualified veterinarians, the high cost of this procedure, and stringent government regulations restricting the import of raw materials are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The veterinary artificial insemination market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The pandemic has disrupted the supply chains for livestock and poultry, reducing the demand for the sale of animal food. Due to inadequate diet and veterinary treatment, including the requirement for timely artificial insemination, pregnancy checks, and deworming, animals suffered. For instance, the Animal Husbandry Department of India started a program in June 2020 that provided telephonic help to poultry farmers and owners to protect farmers and workers against COVID-19. Moreover, during the COVID-19 pandemic, artificial insemination was supplied to farmers' doorsteps. As a result, these activities have helped the market expand.

In contrast, the COVID-19 lockout has had a negative effect on milk producers and processors since there has been a considerable decrease in demand for milk and milk products (MMP). The resulting drop in MMP's pricing has greatly contributed to their stakeholders' losses. Preliminary estimates of economic losses to milk producers stand at 112.3 crores per day, with more than one-fourth of these losses coming from only two states, Uttar Pradesh and Rajasthan. These losses are heavily concentrated in nine states. The increase in consumer welfare brought on by price decreases is insufficient to fully compensate the producers, leaving 66.7 crores in daily economic losses unrecovered. Therefore, lockdown is predicted to cast a lengthy shadow, affecting milk output and the dairy industry's profitability depending on the subsequent mitigating measures taken. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Sexed Semen segment is expected to hold the largest market share in veterinary artificial insemination market

The sexed semen segment is expected to dominate in 2021. The segment benefits from the yields of various breeds, taking into account genetic modification, crossbreeding, and research on the development of certain breeds from sexed semen. According to the evidence, using both normal bovine semen for terminal crosses and sexed semen for purebreds increases meat production in dairy herds. Pregnancy rates in cattle receiving 2 million sexed sperm per insemination dose are almost 80% of those in cattle receiving conventional semen at standard sperm doses.

Nevertheless, since the growth of dairy heifers is essential for the dairy industry and advancements in sexing processes have boosted fertility, approximately 2 million bovine semen applied annually in the United States are sexed. Overall, the data show that, compared to artificial insemination with conventional semen, artificial insemination with sexed semen tends to improve the financial gain of dairy farmers. Additionally, according to the cost-benefit analysis, sexed semen can help the dairy herd expand more quickly and profitably by boosting the number of heifer deliveries. For instance, Sexcel was created using a cutting-edge, patented method for sexing bovine semen, utilizing ABS's best genetics. With this cutting-edge technology, the cells are not subjected to the tremendous pressures, electric currents, and shear forces required to make the sexed semen that farmers can access. Sexcel Sexed Genetics is available for Holstein, Jersey, and Norwegian Red. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global veterinary artificial insemination market

In 2021, North America accounted for the highest revenue share. The increased adoption of artificial insemination procedures in cattle, rising milk consumption and production of beef, growing awareness regarding artificial insemination, expansion and acquisitions by the key market players in the region are some factors the market is expected to boost in the forecast period. For instance, in the U.S., artificial insemination was used in breeding 80% of dairy animals. With over 90% of the market share in North America, the U.S. will be one of the major markets for artificial animal insemination (A.I.) procedures due to their greater adoption rate. Moreover, Semex and Nedap announced the growth of their productive relationship in January 2022. More nations now offer the Semex ai24 program with Nedap technology, allowing dairy farmers to enhance their herds' productivity and performance greatly. Additionally, In April 2021, Elanco Animal Health cooperated with Ducks Unlimited to support agriculture and environmental sustainability, particularly for beef cattle production across North America. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the veterinary artificial insemination market are IMV Technologies, Neogen Corporation, Bovine ELite LLC, Agtech Inc., Zoetis Inc., Jorgensen Labs, Revival Animal Health, Merck Animal Health, Swine Genetics International, Santa Cruz Biotechnology.

Zoetis Inc.:

Overview:

Zoetis is a global animal health company focusing on livestock and companion animals. It is involved in discovering, developing, producing, and marketing animal health drugs, vaccines, and diagnostic tools. Biodevices, genetic diagnostics, and precision livestock farming supplement its goods. The business, among other things, sells vaccines, parasiticides, anti-infective treatments, and medicated feed additives. Its client supply services (CSS) organization also provides contract manufacturing services to other parties. The company has manufacturing sites worldwide. It sells goods through direct marketing channels and distributors in the Americas, Europe, Africa, Asia, and Australia to veterinarians, livestock producers, and people who raise and care for farm and companion animals.

Product Portfolio:

LUTALYSE: The most widely used and approved prostaglandin on the market is LUTALYSE Injection (dinoprost tromethamine injection), which veterinarians recommend. Program for synchronizing artificial insemination with LUTALYSE can increase breeding success. Today, producers and veterinarians have more alternatives than ever for employing LUTALYSE in reproduction programs. Now that FACTREL Injection (gonadorelin injection) has received approval, it can also be used in conjunction with LUTALYSE to synchronize estrous cycles and enable fixed-time artificial insemination (FTAI) in dairy cows that are nursing.

The global veterinary artificial insemination market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.